Christopher Mcleod

Christopher Mcleod is an independent investor, director, and advisor who specializes in early stage life science companies. Christopher has over 25 years of experience in the industry and has held various executive positions during their career.

Christopher began their career as an Executive Vice President at CUC International, a consumer services company. Christopher then became the President and CEO of Cendant Software, a provider of software and services for the hospitality industry. After a two-year tenure, they joined CuraGen Corp. as their Executive Vice President.

In 2006, Christopher became the President of 454 Life Sciences, a next-generation sequencing company. Christopher led the company for six years before moving on to become an investor and director for several early stage life science companies. In 2015, they co-founded AxioMx, Inc., which was acquired by Abcam plc later that year.

Christopher currently serves as a managing partner for Elm Street Ventures, where they focus on investing in and guiding scientists, engineers, and entrepreneurs in New Haven and Connecticut.

Christopher Mcleod has a Bachelor of Science from Yale University in Economics and Engineering & Applied Science from 1977-1979. Christopher also has a Master's degree from the MIT Sloan School of Management in Management from 1979-1981. Lastly, they attended Fairfield Prep from 1969-1973.